Xenpozyme™ (olipudase alfa-rpcp) – New orphan drug approval

Dynamic Alerts

Optum Rx Formulary Changes: Effective 1/1/23 :

Optum guides members and providers through important upcoming formulary updates. See multiple tabs of linked spreadsheet for Select, Premium & UM Changes.

VIEW UPDATES

Site Logo

Health care professionals website

DPL Global Search

DPL Main Nav

DPL Global Search

Breadcrumbs

Text

Xenpozyme^™ (olipudase alfa-rpcp) – New orphan drug approval

August 31, 2022 - The FDA announced the approval of Sanofi’s Xenpozyme (olipudase alfa-rpcp), for treatment of non-central nervous system manifestations of acid sphingomyelinase deficiency (ASMD) in adult and pediatric patients.

Download PDF

Text

Return to publications

Top

RxNews®

Xenpozyme™ (olipudase alfa-rpcp) – New orphan drug approval

Xenpozyme^™ (olipudase alfa-rpcp) – New orphan drug approval